Related Experiment Videos
Leukocyte-derived inhibitory activity in patients with myelodysplastic syndrome
Abstract:
Leukocyte-derived inhibitory activity inhibiting the entry of normal progenitor cells of granulocytes and macrophages (CFU-GM) into the S-phase of a cell cycle was investigated in 16 patients with different forms of myelodysplastic syndrome (MDS). The presence of this inhibitory activity was analysed in medium conditioned with low-density cells obtained from peripheral blood of MDS patients. The inhibition rate was measured by 3H-thymidine suicide technique with subsequent cultivation of pretreated cells in semisolid agar medium. Low-density cells from MDS patients of various types were studied: from the twelve patients with refractory anaemia (RA or RAS) only three were positive, one patient with chronic myelomonocytic leukaemia (CMML) was negative while one patient with refractory anaemia with excess of blasts (RAEB) and two patients with RAEB in transformation (RAEB-T) were positive with respect of the described test. In two patients with RA, who underwent a long-term investigation, the production of leukocyte-derived inhibitory activity preceded the development of disease into RAEB or RAEB-T. In five positive cases, supernatants were incubated with antiserum against human placental ferritin; with one exception, the inhibitory activity was neutralized.
Insights
Leukocyte-derived inhibitory activity hinders normal progenitor cell development in myelodysplastic syndromes (MDS). This inhibitory factor, potentially linked to ferritin, was detected in several MDS subtypes, sometimes preceding disease progression.
Area of Science:
- Hematology
- Cell Biology
- Oncology
Background:
- Myelodysplastic syndromes (MDS) are a group of clonal hematopoietic stem cell disorders.
- Aberrant cell cycle regulation and inhibitory factors are implicated in MDS pathogenesis.
- Leukocyte-derived inhibitory activity's role in MDS requires further elucidation.
Purpose of the Study:
- To investigate leukocyte-derived inhibitory activity in patients with myelodysplastic syndromes (MDS).
- To assess the presence and correlation of this activity with MDS subtypes and disease progression.
- To identify the nature of the inhibitory factor.
Main Methods:
- Collected peripheral blood low-density cells from 16 MDS patients.
- Assessed inhibitory activity on granulocyte-macrophage progenitor cells (CFU-GM) using 3H-thymidine suicide and subsequent cultivation.
- Analyzed inhibitory activity in conditioned media from patient cells.
- Tested neutralization with antiserum against human placental ferritin.
Main Results:
- Leukocyte-derived inhibitory activity was detected in some patients with refractory anemia (RA/RAS), refractory anemia with excess of blasts (RAEB), and RAEB in transformation (RAEB-T).
- The activity was absent in one patient with chronic myelomonocytic leukemia (CMML).
- In two RA patients, inhibitory activity preceded progression to RAEB or RAEB-T. The activity was largely neutralized by anti-ferritin antiserum.
Conclusions:
- Leukocyte-derived inhibitory activity is present in certain MDS subtypes and may play a role in disease progression.
- This activity, potentially related to ferritin, could be a biomarker for MDS.
- Further research is warranted to understand the precise mechanism and clinical implications of this inhibitory activity in MDS.